维生素D受体基因多态与结直肠癌之间缺乏关联:全面的元分析和功率评估
Anu Shibi Anilkumar1, Sheena Mariam Thomas1, Ramakrishnan Veerabathiran2
1Human Cytogenetics and Genomics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu 603103, India.
Critical reviews in eukaryotic gene expression
|March 13, 2026
概括
常见的维生素D受体 (VDR) 基因变异不能预测结直肠癌 (CRC) 风险. 这些VDR多态性不是临床上有用的CRC易感性生物标志物,建议专注于其他预测因素.
科学领域:
- 遗传学和流行病学
- 癌症研究 癌症研究
背景情况:
- 结肠直肠癌 (CRC) 是一个重要的全球健康问题.
- 维生素D受体 (VDR) 基因多态性被研究其在CRC病变发生中的作用.
- 对于CRC风险分层的VDR变异的临床实用性是不确定的.
研究的目的:
- 综合评估常见VDR单核酸多态 (SNP) 与CRC风险之间的关联.
- 确定VDR多态的转化相关性,作为CRC易受性的生物标志物.
主要方法:
- 进行了对24项病例控制研究的元分析.
- 在各种遗传模型下分析了四种常见的VDR SNP (Fok1, Apa1, Bsm1, Taq1).
- 数据来源于主要数据库,统计能力超过0.99.
主要成果:
- 在所有遗传模型中,四种VDR变异和CRC风险之间没有发现统计学意义上的关联.
- 强大的统计能力表明,零结果不是由于样本规模不足造成的.
- 这些常见的VDR多态性缺乏作为CRC敏感性生物标志物的临床功能.
结论:
- 常见的VDR多态性不是预测结直肠癌风险的临床功能生物标志物.
- 应该将资源从这些VDR变异转向更有前途的遗传或分子预测器.
- 进一步的研究应该探索基因与环境的相互作用,包括维生素D状态,饮食和生活方式,用于预防CRC.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121


